Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antineoplastic Combined Chemotherapy Protocols adverse effects"" wg kryterium: Temat


Tytuł :
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Autorzy :
Murthy, R. K.
Loi, S.
Okines, A.
Paplomata, E.
Hamilton, E.
Hurvitz, S. A.
Lin, N. U.
Borges, V.
Abramson, V.
Anders, C.
Bedard, P. L.
Oliveira, M.
Jakobsen, E.
Bachelot, T.
Shachar, S. S.
Muller, V.
Braga, S.
Duhoux, F. P.
Greil, R.
Cameron, D.
Carey, L. A.
Curigliano, G.
Gelmon, K.
Hortobagyi, G.
Krop, I.
Loibl, S.
Pegram, M.
Slamon, D.
Palanca-Wessels, M. C.
Walker, L.
Feng, W.
Winer, E. P.
Pokaż więcej
Temat :
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Brain Neoplasms/secondary
Breast Neoplasms/drug therapy
Capecitabine/administration & dosage
Consolidation Chemotherapy
Diarrhea/chemically induced
Double-Blind Method
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Progression-Free Survival
Protein-Tyrosine Kinases/antagonists & inhibitors
Receptor, ErbB-2/analysis
Trastuzumab/administration & dosage
Źródło :
Murthy, R K, Loi, S, Okines, A, Paplomata, E, Hamilton, E, Hurvitz, S A, Lin, N U, Borges, V, Abramson, V, Anders, C, Bedard, P L, Oliveira, M, Jakobsen, E, Bachelot, T, Shachar, S S, Muller, V, Braga, S, Duhoux, F P, Greil, R, Cameron, D, Carey, L A, Curigliano, G, Gelmon, K, Hortobagyi, G, Krop, I, Loibl, S, Pegram, M, Slamon, D, Palanca-Wessels, M C, Walker, L, Feng, W & Winer, E P 2020, ' Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer ', New England Journal of Medicine, vol. 382, no. 7, pp. 597-609 . https://doi.org/10.1056/NEJMoa1914609
Tytuł :
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Autorzy :
Coleman, Robert L
Fleming, Gini F
Brady, Mark F
Swisher, Elizabeth M
Steffensen, Karina D
Friedlander, Michael
Okamoto, Aikou
Moore, Kathleen N
Efrat Ben-Baruch, Noa
Werner, Theresa L
Cloven, Noelle G
Oaknin, Ana
DiSilvestro, Paul A
Morgan, Mark A
Nam, Joo-Hyun
Leath, Charles A
Nicum, Shibani
Hagemann, Andrea R
Littell, Ramey D
Cella, David
Baron-Hay, Sally
Garcia-Donas, Jesus
Mizuno, Mika
Bell-McGuinn, Katherine
Sullivan, Danielle M
Bach, Bruce A
Bhattacharya, Sudipta
Ratajczak, Christine K
Ansell, Peter J
Dinh, Minh H
Aghajanian, Carol
Bookman, Michael A
Pokaż więcej
Temat :
Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Benzimidazoles/adverse effects
Carboplatin/administration & dosage
Combined Modality Therapy
Cystadenocarcinoma, Serous/drug therapy
Double-Blind Method
Female
Genes, BRCA1
Genes, BRCA2
Humans
Intention to Treat Analysis
Maintenance Chemotherapy
Middle Aged
Mutation
Ovarian Neoplasms/drug therapy
Paclitaxel/administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors/adverse effects
Progression-Free Survival
Quality of Life
Źródło :
Coleman, R L, Fleming, G F, Brady, M F, Swisher, E M, Steffensen, K D, Friedlander, M, Okamoto, A, Moore, K N, Efrat Ben-Baruch, N, Werner, T L, Cloven, N G, Oaknin, A, DiSilvestro, P A, Morgan, M A, Nam, J-H, Leath, C A, Nicum, S, Hagemann, A R, Littell, R D, Cella, D, Baron-Hay, S, Garcia-Donas, J, Mizuno, M, Bell-McGuinn, K, Sullivan, D M, Bach, B A, Bhattacharya, S, Ratajczak, C K, Ansell, P J, Dinh, M H, Aghajanian, C & Bookman, M A 2019, ' Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer ', The New England Journal of Medicine, vol. 381, no. 25, pp. 2403-2415 . https://doi.org/10.1056/NEJMoa1909707
Tytuł :
Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer
Autorzy :
Kopetz, Scott
Grothey, Axel
Yaeger, Rona
Van Cutsem, Eric
Desai, Jayesh
Yoshino, Takayuki
Wasan, Harpreet
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod K.
Arkenau, Hendrik Tobias
Garcia-Alfonso, Pilar
Pfeiffer, Per
Orlov, Sergey
Lonardi, Sara
Elez, Elena
Kim, Tae Won
Schellens, Jan H.M.
Guo, Christina
Krishnan, Asha
Dekervel, Jeroen
Morris, Van
Ferrandiz, Aitana Calvo
Tarpgaard, L. S.
Braun, Michael
Gollerkeri, Ashwin
Keir, Christopher
Maharry, Kati
Pickard, Michael
Christy-Bittel, Janna
Anderson, Lisa
Sandor, Victor
Tabernero, Josep
Pokaż więcej
Temat :
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Benzimidazoles/administration & dosage
Carbamates/administration & dosage
Cetuximab/administration & dosage
Colorectal Neoplasms/drug therapy
Disease Progression
Electrocorticography
Female
Humans
Intention to Treat Analysis
Irinotecan/therapeutic use
Kaplan-Meier Estimate
Male
Middle Aged
Mutation
Proto-Oncogene Proteins B-raf/genetics
Sulfonamides/administration & dosage
Survival Analysis
Źródło :
Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075
Opis pliku :
application/pdf
Tytuł :
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Autorzy :
Grabsch, HI
Slagter, AE
Jansen, EPM
van Laarhoven, HWM
van Sandick, JW
van Grieken, NCT
Sikorska, K
Cats, A
Muller-Timmermans, P
Hulshof, MCCM
Boot, H
Los, M
Beerepoot, LV
Peters, FPJ
Hospers, GAP
van Etten, B
Hartgrink, HH
Henegouwen, MIVB
Nieuwenhuijzen, GAP
van Hillegersberg, R
van der Peet, DL
Verheij, M
Pokaż więcej
Temat :
ADJUVANT CHEMOTHERAPY
Neoplasm Staging
CLINICAL-TRIAL
Preoperative treatment
OPEN-LABEL
Chemotherapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
LYMPH-NODE DISSECTION
Neoplasm Grading
Gastrectomy/methods
PERIOPERATIVE CHEMOTHERAPY
Stomach Neoplasms/mortality
Neoplasm Metastasis
Combined Modality Therapy
Study Protocol
Chemotherapy, Adjuvant/methods
CURATIVE RESECTION
D2 GASTRECTOMY
PREOPERATIVE CHEMORADIOTHERAPY
Female
Resectable
GASTROESOPHAGEAL JUNCTION
Gastric cancer
Chemoradiotherapy
Neoadjuvant Therapy/methods
Treatment Outcome
Follow-Up Studies
Chemoradiotherapy, Adjuvant/methods
RC254-282
PLUS CISPLATIN
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Quality of Life
Humans
Male
Surgery
Źródło :
BMC Cancer, 18(1). BioMed Central Ltd
BMC Cancer, Vol 18, Iss 1, Pp 1-12 (2018)
BMC cancer, 18(1). BioMed Central
BMC Cancer, 18(1). BioMed Central
Opis pliku :
application/pdf
Tytuł :
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Autorzy :
de Boer, Stephanie M.
Powell, Melanie E.
Mileshkin, Linda
Katsaros, Dionyssios
Bessette, Paul
Haie-Meder, Christine
Ottevanger, Petronella B.
Ledermann, Jonathan A.
Khaw, Pearly
Colombo, Alessandro
Fyles, Anthony
Baron, Marie Helene
Jürgenliemk-Schulz, Ina M.
Kitchener, Henry C.
Nijman, Hans W.
Wilson, Godfrey
Brooks, Susan
Carinelli, Silvestro
Provencher, Diane
Hanzen, Chantal
Lutgens, Ludy C.H.W.
Smit, Vincent T.H.B.M.
Singh, Naveena
Do, Viet
D'Amico, Romerai
Nout, Remi A.
Feeney, Amanda
Verhoeven-Adema, Karen W.
Putter, Hein
Creutzberg, Carien L.
McCormack, Mary
Whitmarsh, Karen
Allerton, Rozenn
Gregory, Deborah
Symonds, Paul
Hoskin, Peter J.
Adusumalli, Madhavi
Anand, Anjana
Wade, Robert
Stewart, Alexandra
Taylor, Wendy
Kruitwagen, Roy F.P.M.
Hollema, Harry
Pras, Elizabeth
Snyers, An
Stalpers, Lukas
Jobsen, Jan J.
Slot, Annerie
Mens, Jan Willem M.
Stam, Tanja C.
Pokaż więcej
Temat :
Carboplatin/administration & dosage
no
Comparative Study
Neoplasm Staging
Cisplatin/administration & dosage
Oncology
Carcinoma, Endometrioid/mortality
Paclitaxel/administration & dosage
Research Support, Non-U.S. Gov't
New Zealand
Neoplasm Grading
Time Factors
Endometrial Neoplasms/mortality
Dose Fractionation, Radiation
Female
Europe
Risk Factors
Chemoradiotherapy, Adjuvant/adverse effects
Aged
Australia
Middle Aged
Treatment Outcome
Clinical Trial, Phase III
Randomized Controlled Trial
Gynecologic Surgical Procedures/adverse effects
Lymph Node Excision
Canada
Multicenter Study
Journal Article
Radiotherapy, Adjuvant
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Humans
Źródło :
PORTEC study group 2018, ' Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 3, pp. 295-309 . https://doi.org/10.1016/S1470-2045(18)30079-2
lancet oncology, 19(3), 295 - 309. Lancet Publishing Group
The Lancet Oncology, 19(3), 295. Lancet Publishing Group
Opis pliku :
image/pdf
Tytuł :
Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx(®)):a placebo-controlled randomised phase II study (PLIANT)
Autorzy :
Glimelius, Bengt
Manojlovic, Nebojsa
Pfeiffer, Per
Mosidze, Baadur
Kurteva, Galina
Karlberg, Mia
Mahalingam, Devalingam
Buhl Jensen, Peter
Kowalski, Jan
Bengtson, Marie
Nittve, Malin
Näsström, Jacques
Pokaż więcej
Temat :
Adult
Aged
Antineoplastic Agents/adverse effects
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Colorectal Neoplasms/drug therapy
Disease-Free Survival
Double-Blind Method
Edetic Acid/analogs & derivatives
Female
Fluorouracil/adverse effects
Humans
Kaplan-Meier Estimate
Leucovorin/adverse effects
Male
Middle Aged
Organoplatinum Compounds/adverse effects
Peripheral Nervous System Diseases/chemically induced
Pyridoxal Phosphate/analogs & derivatives
Źródło :
Glimelius, B, Manojlovic, N, Pfeiffer, P, Mosidze, B, Kurteva, G, Karlberg, M, Mahalingam, D, Buhl Jensen, P, Kowalski, J, Bengtson, M, Nittve, M & Näsström, J 2018, ' Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx(®)) : a placebo-controlled randomised phase II study (PLIANT) ', Acta Oncologica, vol. 57, no. 3, pp. 393-402 . https://doi.org/10.1080/0284186X.2017.1398836
Tytuł :
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Autorzy :
de Boer, Stephanie M.
Powell, Melanie E.
Mileshkin, Linda
Katsaros, Dionyssios
Bessette, Paul
Haie-Meder, Christine
Ottevanger, Petronella B.
Ledermann, Jonathan A.
Khaw, Pearly
Colombo, Alessandro
Fyles, Anthony
Baron, Marie-Helene
Jurgenliemk-Schulz, Ina M.
Kitchener, Henry C.
Nijman, Hans W.
Wilson, Godfrey
Brooks, Susan
Carinelli, Silvestro
Provencher, Diane
Hanzen, Chantal
Lutgens, Ludy C. H. W.
Smit, Vincent T. H. B. M.
Singh, Naveena
Do, Viet
D'Amico, Romerai
Nout, Remi A.
Feeney, Amanda
Verhoeven-Adema, Karen W.
Putter, Hein
Creutzberg, Carien L.
Pokaż więcej
Temat :
Carboplatin/administration & dosage
Neoplasm Staging
Cisplatin/administration & dosage
GYNECOLOGIC-ONCOLOGY-GROUP
CHEMOTHERAPY
Paclitaxel/administration & dosage
Carcinoma, Endometrioid/mortality
New Zealand
Neoplasm Grading
Time Factors
Endometrial Neoplasms/mortality
CLINICAL-TRIALS
Dose Fractionation, Radiation
Female
Europe
Risk Factors
Chemoradiotherapy, Adjuvant/adverse effects
Aged
Australia
Middle Aged
PROGNOSIS
Treatment Outcome
Article
RECURRENCE
RADIATION-THERAPY
III TRIAL
Gynecologic Surgical Procedures/adverse effects
Lymph Node Excision
CARCINOMA PATIENTS
Canada
QUALITY-OF-LIFE
Radiotherapy, Adjuvant
STAGE-I
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Humans
Źródło :
Lancet oncology, 19(3), 295 - 309. Elsevier Science
Lancet Oncology, 19(3), 295 - 309. ELSEVIER SCIENCE INC
Opis pliku :
application/pdf
Tytuł :
Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer
Autorzy :
Rosvig, Lena H
Langkjer, Sven T
Knoop, Ann
Jensen, Anders B
Pokaż więcej
Temat :
Journal Article
Humans
Middle Aged
Palliative Care
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Disease Progression
Deoxycytidine/administration & dosage
Receptors, Estrogen/metabolism
Retreatment
Neoplasm Metastasis
Adult
Carboplatin/administration & dosage
Female
Aged
Trastuzumab/administration & dosage
Breast Neoplasms/drug therapy
Receptor, ErbB-2/metabolism
Źródło :
Rosvig, L H, Langkjer, S T, Knoop, A & Jensen, A B 2018, ' Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer ', Acta Oncologica, vol. 57, no. 1, pp. 156-159 . https://doi.org/10.1080/0284186X.2017.1407495
Tytuł :
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer:Randomized phase II study
Autorzy :
Han, H. S.
Diéras, V.
Robson, M.
Palácová, M.
Marcom, P. K.
Jager, A.
Bondarenko, I.
Citrin, D.
Campone, M.
Telli, M. L.
Domchek, S. M.
Friedlander, M.
Kaufman, B.
Garber, J. E.
Shparyk, Y.
Chmielowska, E.
Jakobsen, E. H.
Kaklamani, V.
Gradishar, W.
Ratajczak, C. K.
Nickner, C.
Qin, Q.
Qian, J.
Shepherd, S. P.
Isakoff, S. J.
Puhalla, S.
Pokaż więcej
Temat :
Metastatic breast cancer
PARP inhibitors
Platinum
Temozolomide
Single-Blind Method
Humans
Middle Aged
Male
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Temozolomide/administration & dosage
Young Adult
Neoplasm Metastasis
Genes, BRCA2
Germ-Line Mutation
Placebos
Adult
Female
Genes, BRCA1
Breast Neoplasms/drug therapy
Benzimidazoles/administration & dosage
Neoplasm Recurrence, Local/drug therapy
Paclitaxel/administration & dosage
Breast Neoplasms, Male/drug therapy
Carboplatin/administration & dosage
Aged
Źródło :
Han, H S, Diéras, V, Robson, M, Palácová, M, Marcom, P K, Jager, A, Bondarenko, I, Citrin, D, Campone, M, Telli, M L, Domchek, S M, Friedlander, M, Kaufman, B, Garber, J E, Shparyk, Y, Chmielowska, E, Jakobsen, E H, Kaklamani, V, Gradishar, W, Ratajczak, C K, Nickner, C, Qin, Q, Qian, J, Shepherd, S P, Isakoff, S J & Puhalla, S 2018, ' Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer : Randomized phase II study ', Annals of Oncology, vol. 29, no. 1, pp. 154-161 . https://doi.org/10.1093/annonc/mdx505
Tytuł :
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
Autorzy :
Eichenauer, Dennis A
Becker, Ingrid
Monsef, Ina
Chadwick, Nicholas
de Sanctis, Vitaliana
Federico, Massimo
Fortpied, Catherine
Gianni, Alessandro M
Henry-Amar, Michel
Hoskin, Peter
Johnson, Peter
Luminari, Stefano
Bellei, Monica
Pulsoni, Alessandro
Sydes, Matthew R
Valagussa, Pinuccia
Viviani, Simonetta
Engert, Andreas
Franklin, Jeremy
Pokaż więcej
Temat :
Odds Ratio
Article
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Disease-Free Survival
Follow-Up Studies
Hodgkin Disease
Humans
Neoplasms, Second Primary
Proportional Hazards Models
Randomized Controlled Trials as Topic
Hematology
Hodgkin Lymphoma
Neoplasms, Second Primary/etiology
Combined Modality Therapy/adverse effects
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Hodgkin Disease/mortality
Źródło :
Eichenauer, D A, Becker, I, Monsef, I, Chadwick, N, de Sanctis, V, Federico, M, Fortpied, C, Gianni, A M, Henry-Amar, M, Hoskin, P, Johnson, P, Luminari, S, Bellei, M, Pulsoni, A, Sydes, M R, Valagussa, P, Viviani, S, Engert, A & Franklin, J 2017, ' Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma : a systematic review and meta-analysis of randomized clinical trials ', Haematologica, vol. 102, no. 10, pp. 1748-1757 . https://doi.org/10.3324/haematol.2017.167478
Opis pliku :
application/pdf; text
Tytuł :
Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites
Autorzy :
Toksvang, Linea Natalie
De Pietri, Silvia
Nielsen, Stine N.
Nersting, Jacob
Albertsen, Birgitte Klug
Wehner, Peder S.
Rosthøj, Steen
Lähteenmäki, Päivi M.
Nilsson, Daniel
Nystad, Tove A.
Grell, Kathrine
Frandsen, Thomas Leth
Schmiegelow, Kjeld
Pokaż więcej
Temat :
Acute lymphoblastic leukemia
Asparaginase
Liver toxicity
Maintenance therapy
Sinusoidal obstruction syndrome
Hepatic Veno-Occlusive Disease/chemically induced
Humans
Kaplan-Meier Estimate
Proportional Hazards Models
Child, Preschool
Infant
Male
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Mercaptopurine/administration & dosage
Methotrexate/administration & dosage
Drug Interactions
Adolescent
Asparaginase/administration & dosage
Female
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
Maintenance Chemotherapy
Polyethylene Glycols/administration & dosage
Child
Źródło :
Toksvang, L N, De Pietri, S, Nielsen, S N, Nersting, J, Albertsen, B K, Wehner, P S, Rosthøj, S, Lähteenmäki, P M, Nilsson, D, Nystad, T A, Grell, K, Frandsen, T L & Schmiegelow, K 2017, ' Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites ', Pediatric Blood & Cancer, vol. 64, no. 9, e26519 . https://doi.org/10.1002/pbc.26519

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies